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Abstract
Background: The technique of percutaneous aortic valve implantation (PAVI) for the treatment
of severe aortic stenosis (AS) has been introduced in 2002. Since then, many thousands such
devices have worldwide been implanted in patients at high risk for conventional surgery. The
procedure related mortality associated with PAVI as reported in published case series is substantial,
although the intervention has never been formally compared with standard surgery. The objective
of this study was to assess the safety of PAVI, and to compare it with published data reporting the
risk associated with conventional aortic valve replacement in high-risk subjects.
Methods: Studies published in peer reviewed journals and presented at international meetings
were searched in major medical databases. Further data were obtained from dedicated websites
and through contacts with manufacturers. The following data were extracted: patient
characteristics, success rate of valve insertion, operative risk status, early and late all-cause
mortality.
Results: The first PAVI has been performed in 2002. Because of procedural complexity, the
original transvenous approach from 2004 on has been replaced by the transarterial and transapical
routes. Data originating from nearly 2700 non-transvenous PAVIs were identified. In order to
reduce the impact of technical refinements and the procedural learning curve, procedure related
safety data from series starting recruitment in April 2007 or later (n = 1975) were focused on. One-
month mortality rates range from 6.4 to 7.4% in transfemoral (TF) and 11.6 to 18.6% in transapical
(TA) series. Observational data from surgical series in patients with a comparable predicted
operative risk, indicate mortality rates that are similar to those in TF PAVI but substantially lower
than in TA PAVI. From all identified PAVI series, 6-month mortality rates, reflecting both
procedural risk and mortality related to underlying co-morbidities, range from 10.0-25.0% in TF
and 26.1-42.8% in TA series. It is not known what the survival of these patients would have been,
had they been treated medically or by conventional surgery.
Conclusion: Safety issues and short-term survival represent a major drawback for the
implementation of PAVI, especially for the TA approach. Results from an ongoing randomised
controlled trial (RCT) should be awaited before further using this technique in routine clinical
practice. In the meantime, both for safety concerns and for ethical reasons, patients should only be
subjected to PAVI within the boundaries of such an RCT.
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The first human percutaneous aortic valve implantation
(PAVI) has been performed by Cribier in April 2002[1].
The initial antegrade transvenous technique through the
interatrial septum later on was replaced by the retrograde
transarterial approach. For patients in whom vascular
access was rendered impossible due to severe atheroma-
tous disease, the transapical route was designed, where
PAVI occurs directly through the left ventricular apex,
involving a mini-thoracotomy. So far, results from over
3500 PAVIs have been made public[2,3]. Although both
European[4] and American[5] professional organisations
emphasise safety issues, many single or multiple case
series continue to be reported. We recently performed a
Health Technology Assessment on PAVI[6]. The safety
issues emerging from this review are discussed here.
Methods
On December 15, 2008, both authors searched Medline,
Embase, Cochrane Library, and CRD databases, using rel-
evant subject headings and a collection of text words rep-
resenting the concept of PAVI. Furthermore, internet-
based sources dedicated to dissemination of results from
cardiovascular trials http://www.tctmd.com, http://
www.medscape.com were searched. We also contacted
interventional cardiologists and manufacturers. Full
details of the search strategy have been described else-
where[6] and are accessible from our website http://
www.kce.fgov.be/
index_en.aspx?SGREF=10504&CREF=12227. To be eligi-
ble for inclusion, studies had to report experience with
transarterial or transapical PAVI in patients with severe
symptomatic aortic stenosis (AS). Transvenous PAVI was
not considered. Single-case reports were excluded because
of their obvious anecdotal nature. Only devices that have
been granted European CE marking were taken into con-
sideration: the Edwards Lifesciences device (or any of its
predecessors) and the CoreValve Revalving System. The
CE marking denotes a formal statement by the manufac-
turer of compliance with EU directives requirements.
Unlike the pharmaceutical sector, where new drugs have
to undergo series of regulatory clinical trials during devel-
opment, the evaluation of medical devices is less demar-
cated and no pre-market clinical trials are required for
obtaining CE marking[7].
The following data were extracted: operative risk score,
valve type and approach, number of patients in the series,
time frame of the series, implantation success rate, proce-
dural (defined as 30-day) mortality, and longer term mor-
tality if available.
Results
CRD and the Cochrane database revealed no systematic
reviews on PAVI. No data from randomised controlled tri-
als (RCTs) were identified. The National Institutes of
Health clinical trials registry http://www.clinicaltrials.gov
mentioned one RCT in progress. Our selection process
resulted in 15 case series that further in this review are
referred to as "published series". Extracted data are
depicted in Table 1.
Unpublished data were obtained through contacts with
manufacturers and from webposted 2008 conference pro-
ceedings: EuroPCR08, Transcatheter Valve Therapy, Euro-
pean Association for Cardio-Thoracic Surgery and
Transcatheter Cardiovascular Therapeutics. These unpub-
lished data are referred to as "presented series" further in
this review. Thirteen case series (Table 2) with a dedicated
acronym were identified; reference to these in the pub-
lished series rarely occurred. Based on the names of partic-
ipating authors and on the time window of patient
recruitment, it seems that most of the cases that have been
discussed in published papers are part of the presented
series. Patient characteristics and outcome data from pre-
sented series are provided in Table 2. Data from 2692
patients were identified, 76% of which were treated via
the transfemoral (TF) and 24% via the transapical (TA)
route. Their mean age was about 82 years. In all series
operative risk was estimated by means of the logistic Euro-
SCORE http://www.euroscore.org. Some series did also
provide the risk by the Society of Thoracic Surgeons (STS)
risk tool http://www.sts.org. The EuroSCORE of TF treated
patients was lower than that of TA treated subjects. Data
related to the same registry were not always identical from
different sources. In Table 2, we entered the most recently
presented data that we could identify. Technical success of
PAVI was not always defined in the same way among dif-
ferent registries. For example, in a report of the PARTNER
EU registry, Lefèvre reports a 96.3% success rate (52/54),
although PAVI was reportedly aborted in 6 patients out of
60 planned because of vascular access problems, a failed
balloon valvuloplasty or the detection of endocarditis[8]
Incorporating these data would result in a success rate of
86.7% (52/60).
In order to reduce the impact of technical refinements and
the procedural learning curve, a summary estimate of
PAVI safety is calculated from series starting recruitment
in April 2007 or later (n = 1975). In these registries, one-
month mortality rates range from 6.4 to 7.4% in TF and
11.6 to 18.6% in TA series. From all identified PAVI series,
six-month mortality ranges from 10-25.0% following TF
and 26.1-42.8% following TA procedures.
Discussion
By introducing a percutaneous approach for aortic valve
insertion, it was hypothesised that elderly and frail
patients in whom this less-invasive procedure was per-
formed would run a lower procedural risk than whenPage 2 of 7
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(AVR)[9]. Since the first PAVI in 2002, many thousands
such devices have been implanted worldwide. In the ini-
tial antegrade transseptal approach a procedure attributa-
ble mortality risk of 25% was noted,[10] which initiated
the development of the less demanding retrograde TF
technique. The latter can however be hampered due to dif-
ficulties to advance large catheters through tortuous and
diffusely diseased femoral and iliac arteries, often encoun-
tered in elderly people. These restrictions have led to the
development of the TA approach where the same device is
introduced from the cardiac apex via a mini-thoracotomy.
Due to this selection process, patients treated by the TA
route mostly have a higher risk profile than those treated
by the TF approach which is reflected in their higher Euro-
SCORE.
The available data demonstrate that even at experienced
centers, PAVI remains a risky procedure. In series starting
recruitment in April 2007 or later, i.e. after European mar-
ket approval, one-month mortality rates range from 6.4 to
7.4% in TF and 11.6 to 18.6% in TA series. In these
patients, it is uncertain what their survival would have
been if they had been operated conventionally or treated
medically. It also remains unclear to what extent a
patient's overall quality of life is improved by the proce-
dure, provided he or she survives the intervention. There
are no sound criteria to assess the appropriateness to pro-
Table 1: Data extracted from "published series"
Reference Time window n Age in years 
mean ± SD 
(median: IQR)
Logistic 
EuroSCORE 
mean ± SD 
(median: IQR)
STS score Device, 
approach
Success 
rate (%)
30-d mort 
(%)
6-m mort 
(%)
[27] Jan 2005 - July 2005 18 81 ± 6 26.2 ± 13.1 NA Ed, TF 77.8 11.1 NA
[23] Jan 2005 - NA 50 82 ± 7 28 NA Ed, TF 86 12 18
[28] Feb 2005 - Nov 2005 25 80.3 ± 5.4
(10.97:19.90-
9.20)
NA CV, TF 84 20 NA
[29] March 2005 - Aug 
2006
11 81.8 ± 6.8 (36: 5-48) NA CV, TF 100 18.2 NA
[30] Aug 2005 - Feb 2007 86 82.2 ± 5.9 21.7 ± 12.6 NA CV, TF 88 12 NA
[31] Oct 2005 - NA 7 63-91 range: 7-66 NA Ed, TA 100 14.3 42.8
[32]§ Oct 2005 - NA 7 63-91 range: 7-66 NA Ed, TA § § §
[33] Dec 2005 - Aug 2006 10 (81.3: 64-85) (32: 21-40) NA CV, TF 100 20 NA
[34] Feb 2006 - Sep 2006 30 82 ± 5 27.1 ± 12.2 NA Ed, TA 96.6 6.6 NA
[35] Feb 2006 - March 
2007
50 82.4 ± 4.6 276 ± 12.2 15.8 ± 9.1 Ed, TA 94 8 26.1
[21] Feb 2006 - Oct 2006 59 81.4 ± 5.8 26.8 ± 13.5 NA Ed, TA 93.2 13.6 NA
[36] Feb 2006 - Feb 2008 26 84 ± 7 36.5 ± 5.8 NA Ed, TA 100 15 NA
[37] Oct 2006 - Apr 2007 12 85 ± 6 31.1 ± 14.4 18.8 ± 4.3 Ed, TF 83 25 25
[14] Dec 2006 - Feb 2008 40 83 ± 7.5 35.5 ± 15.3 13.4 Ed, TA 87.5 17.5 41.3
[38] April 2007 - January 
2008
22 84 ± 7 26 ± 16* Ed, TF+TA 91 9.1 NA
NA: not available. Ed: Edwards Lifesciences device (or any of its predecessors). CV: CoreValve Revalving System. TF: transfemoral. TA: transapical. § 
6-month follow-up of data from [31] *: risk estimation tool not mentioned. SD: standard deviation. IRQ: interquartile range. NA: not available. 
Success: % of attempted successful. STS: Society of Thoracic Surgeons.Page 3 of 7
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gery or PAVI) in frail elderly patients with substantial co-
morbidities. Depending on the pre-procedural clinical
condition that remains unaffected by correcting the AS,
the quality of life may hardly be altered by a successful
PAVI. In this respect, recent guidelines state that "valve
replacement is technically possible at any age, but the
decision to proceed with such surgery depends on many
factors ... Deconditioned and debilitated patients often do
not return to an active existence, and the presence of the
other comorbid disorders could have a major impact on
outcome[11]."
In a literature review on AVR in the octogenarian, opera-
tive mortality of isolated AVR varied between 4.3 and
10.3%[12]. Very recently operative results of 1000 "mini-
mally invasive" (i.e. parasternal approach or hemisternot-
omy) AVRs were reported. Among 160 patients of 80 years
Table 2: Data extracted from "presented series"
Registry acronym Time window n Age Logistic 
EuroSCORE
STS score Success 
rate (%)
30-d 
mort
6-m 
mort
1-yr 
mort
Data 
source
Transfemoral Edwards Lifesciences PAVI
VANCOUVER Jan 2005 - NA 114 84° 28° 9.1° 92.1 7.9 13** 20** [39]
REVIVAL 2 Dec 2005 - Feb 2008 55 82.8 ± 6.8 34.1 ± 18.0 13.1 ± 7.2 87.3 7.3 16.6 24.2 [40,41]
REVIVE 2 NA - Dec 2007 106 83.9 ± 5.4 29.9 ± 13.2 NA 88.0 13.2 21.4 28.6 [40,41]
PARTNER EU April 2007 - Jan 2008 60 82.5 ± 5.2 24.7 ± 11.7 10.9 ± 5.9 96.3 7.4 10 NA [8]
SOURCE Nov 2007 - Sep 2008 293 81.8 26.4 NA 97.7 6.4 NA NA [8]
Transfemoral CoreValve PAVI
CoreValve 21F S&E Aug 2005 - 2006 52 81.4 ± 5.5 27.4 ± 15.1 NA 90.4 15.4 23** 35** [2]
CoreValve 18F S&E May 2006 - Oct 2007 124 81.8 ± 6.5 23.0 ± 13.5 NA 94.4 14.5 23** 28** [2]
CoreValve 18F EE April 2007 - Sep 2008 1243 81.2 ± 6.4 22.9 ± 14.1 NA 98.2 6.7 21° NA [2,40]
TOTAL 
TRANSFEMORAL
2047 7.8
Transapical Edwards Lifesciences PAVI
VANCOUVER Oct 2005 - NA 58 84° 28° 9.1° 98.3 19.0 34 34 [39]
REVIVAL 2 Dec 2005 - Feb 2008 40 83.7 ± 5.2 35.5 ± 15.3 13.4 ± 7.0 87.5 17.6 35.8 45.3 [3,14]
TRAVERCE Dec 2004 - April 
2008
168 82.0 ± 5.6 26.9 ± 12.8 NA 92.9 14.9 30 35 [41]
PARTNER EU April 2007 - Jan 2008 70 82.1 ± 5.7 33.5 ± 14.8 11.9 ± 7.0 91 18.6 42 NA [8]
SOURCE Nov 2007 - Sep 2008 309 80.7 30 NA NA 11.6 NA NA [42]
TOTAL 
TRANSAPICAL
645 13.8
Registry acronyms: VANCOUVER: Vancouver single-centre experience; REVIVAL 2: peRcutaneous EndoVascular Implantation of VALves; REVIVE 2: 
Registry of EndoVascular Implantation of Valves in Europe; PARTNER EU: Placement of AoRTic TraNscathetER Valve Trial; SOURCE: edwards 
Sapien aOrtic bioprothesis eURropean outComE registry; CoreValve 21F S&E: 21 French safety and efficacy registry; CoreValve 18F S&E: 18 French 
safety and efficacy registry; CoreValve 18F EE: 18 French post CE mark Expanded Evaluation registry; TRAVERCE: TRAnsapical Surgical DeliVEry of 
the Cribier-Edwards aortic bioprosthesis. TF: transfemoral. TA: transapical. PAVI: percutaneous aortic valve insertion. *: 18 French and 21 French 
refer to the outer diameter of the delivery sheath. **: estimated from Kaplan Meier survival plot. °: data from TF and TA series combined.Page 4 of 7
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was 1.9%[13]. Svensson et al. report the fate of 163
patients that were referred to their institutions for poten-
tial PAVI because of putative inoperability[14]. Twenty
nine of them were treated by conventional AVR with no
operative deaths. High-surgical-risk and operability status
are poorly defined concepts and complicate the interpre-
tation of outcomes from observational data. The operative
risk of patients contemplated for PAVI have mostly been
estimated through the EuroSCORE but its performance in
high-risk patients has been critisised [15-19]. Recent
observational data from surgically treated patients indi-
cate that the EuroSCORE severely overestimates postoper-
ative mortality in high-risk patients undergoing an
isolated AVR. In a surgical series from the Mayo Clinic, a
predicted 30-day mortality of 23.6% sharply contrasted
with an observed mortality of only 5.8%[20]. By compar-
ing this figure with 30-day mortality rates observed in
PAVI (Table 2), it could be argued that patients with AS
that are considered at high risk for conventional surgery,
may actually run a higher mortality risk if treated by
means of PAVI than when treated surgically. Only data
from an RCT would enable to clarify this.
Six-month mortality of patients treated by PAVI, reflecting
both procedural risk and mortality from underlying co-
morbidities, is also very high and ranges from 10-25.0%
in TF series and 26.1-42.8% in TA series (Tables 1 and 2).
The wide range in the observed short term mortality rate
may result from the chosen interventional approach for
PAVI and from differences in patient selection. The Euro-
SCORE does not take into account several conditions that
are often encountered in elderly patients, yet are determi-
nants for both life expectancy and quality of life, even fol-
lowing successful PAVI: coronary artery disease, heart
failure, diabetes, presence and degree of mitral regurgita-
tion, arrhythmias, previous stroke, renal failure on dialy-
sis[21,22]. This might explain that in a series of 50
patients reported by Webb, 6-month survival of 7 patients
in whom PAVI failed (86%) was similar to 6-month sur-
vival of 43 successfully treated cases (81%)[23].
One-year survival after PAVI ranges from 65-80% in TF
series and from 54.7-66% in TA series. In an observational
study encompassing 277 elderly patients (> 80 years) 80
underwent surgical AVR and 197 were treated medically.
One-year survival among patients with AVR was 87%,
compared with 52% in those who had no AVR[24]. Data
from the European Heart Survey showed a 1-year survival
among 72 patients (> 75 years old) with severe sympto-
matic AS in whom it was decided not to operate, of 84.8 ±
4.8%[25]. In a US series of 75 unoperated patients aged
68.1 ± 15.0 years, with severe symptomatic AS, one-year
survival was 62%[26]. The poor one-year survival of
patients following PAVI overlaps with that of patients
treated conservatively. This can at least partly be explained
by a high procedural mortality rate and the very poor gen-
eral condition with inherent competing mortality risk of
the patients involved, questioning the appropriateness of
an intervention directed towards a correction of the AS in
this population.
The major shortcoming of published series and cases pre-
sented at international meetings, the data of which are
summarised here, is the lack of randomisation of eligible
patients to an intervention group treated with PAVI, ver-
sus a control group. Moreover, data published in peer
reviewed journals reflect the experience of specified
authors, whereas the data from compiled PAVI series pre-
sented at meetings are entirely under control of the man-
ufacturers involved. Participation in some of the registries
and the reporting of outcomes in some instances is on a
voluntary basis only. We were unable to verify the com-
pleteness and the correctness of reported mortality rates.
One-year mortality rates that are referred to in this paper
obviously stem from earlier series, and may not be appli-
cable to more recent experience. Therefore, the results of
our study and from any non-randomised trial should be
interpreted with caution.
Although data from an increasing number of patients are
published in journals and presented at meetings, they do
not add to our understanding of the potential of this new
technology. The methodological shortcomings prevailing
in all these series remain unaltered, i.e. the data are merely
observational from selected and unrandomised patient
groups.
Conclusion
The safety issues pointed out above reinforce the conten-
tion that an RCT is badly needed to clarify the safety and
the performance of PAVI in frail and elderly patients. In
the years to come, evidence will be provided by an ongo-
ing RCT, the PARTNER-IDE (ClinicalTrials.gov identifier
NCT00530894)[3]. One might wonder whether in the
meantime subjecting patients to PAVI can be justified.
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